Navigation Links
Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/30/2009

>Final results from two Phase 1b trials of PX-12, an inhibitor of thioredoxin, were presented by Dr. R.K. Ramanathan, Scottsdale Clinical Research Center, Scottsdale, Arizona. These trials in 32 patients were designed to assess the tolerability and pharmacodynamic activity of both 24-hour and 72-hour infusions of PX-12. In both trials, doses up to 400 mg/m(2)/day were well-tolerated. PX-12 was shown to lower levels of circulating thioredoxin in patients whose starting levels were at least three-fold greater than normal. Three patients achieved stable disease.

About Stimuvax

Stimuvax is an investigational therapeutic cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a glycoprotein antigen widely expressed on common cancers. MUC1 is over-expressed on many cancers such as lung cancer, breast cancer, prostate cancer and colorectal cancer. Stimuvax is thought to work by stimulating the body's immune system to identify and destroy cancer cells expressing MUC1. Merck KGaA currently is conducting a global Phase 3 trial of Stimuvax known as START (Stimulating Targeted Antigenic Responses To NSCLC). START is a randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage III NSCLC who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The Phase 3 trial is expected to enroll more than 1,300 patients in over 30 countries. For more information on the START trial, or to find a participating center and eligibility criteria, log on to www.nsclcstudy.com or www.clinicaltrials.gov.

About PX-866

PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Aberrant activation and regu
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
(Date:9/18/2014)... group of rare diseases that afflict skeletal growth ... hits at the fetal stage and is caused ... encoding fibroblast growth factor receptor 3 (FGFR3) has ... thanatophoric dysplasia (TD), a skeletal dysplasia that cause ... lethal, and achondroplasia (ACH), which causes stunted growth ...
(Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
(Date:9/18/2014)... September 24 marks ASEA's "Meet ASEA" grand ... manufacturer of the world's first and only redox signaling ... , The Mexico City event features renowned speakers Dr. ... Field Leader Shawn Catmull from Draper, UT. , Dr. ... from the University of Utah and devotes his career ...
Breaking Biology Technology:1974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Using solar energy to turn raw materials into ingredients for every day life 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2
... ON ALS CLINICALS AND DRUG DEVELOPMENT, ROCKVILLE, ... (Amex: CUR ) announced that Dr. Thomas ... President, Research. He will be,working with Dr. Karl ... the company,s upcoming clinical trial for ALS,(Amytrophic Lateral ...
... Symbol: MS, EDMONTON, July 30 /PRNewswire-FirstCall/ - BioMS ... of multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... "Focus on Healthcare Conference" in New York., ... WHERE: The Millennium Broadway Hotel, New York ...
... receives custom orders from leading semiconductor manufacturers, officially putting revenue ... ... Seattle, WA (PRWEB) July 30, 2008 -- Carbon Nanoprobes, Inc ... welcomes its first revenue from two major semiconductor manufacturers. Contracts ...
Cached Biology Technology:Neuralstem Fills Key Product Development Position 2BioMS Medical to present at BMO Healthcare Conference 2Startup Nanotech Firm Books First Revenue From Large Chip Makers 2Startup Nanotech Firm Books First Revenue From Large Chip Makers 3
(Date:9/17/2014)... decades of decline, grasses have returned to some once-denuded ... marsh in those places seems healthy again, but a ... the marsh coastal protection remains diminished. , ... hasn,t come back," said ecologist Mark Bertness, professor of ... in the journal Biological Conservation . "The metric ...
(Date:9/17/2014)... a new crime unit designed to fight food fraud ... horse meat being passed off as beef scientists ... adulteration. They describe their approach, which represents a vast ... Agricultural and Food Chemistry . , Hans-Ulrich Humpf and ... economic problem. But they also say that adding, for ...
(Date:9/17/2014)... bacterial infections, including MRSA and MSSA could be ... that mimic the scaly surface of shark skin, ... journal Antimicrobial Resistance and Infection Control . ... prevented the spread of human disease bacteria through ... is an arrangement of ridges formulated to resemble ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Sharks' skin has teeth in the fight against hospital superbugs 2
... Researchers at Indiana University School of Medicine are several steps closer ... cells could be used to let him or her hear the ... able to transform, in the laboratory, stem cells taken from adult ... nerve cells -- neurons -- found in the ear. The results ...
... at New York University and Rockefeller University have ... shown to have key roles in gene regulation, ... mammals. MicroRNAs are a recently discovered large class ... complementary sites in target messenger RNA to regulate ...
... to visualize more of the arteries in the lungs, ... seeing more may have little impact on the patient's ... 198 patients with suspected pulmonary embolism. About half of ... 100 patients had a single-detector CT examination. The radiology ...
Cached Biology News:Researchers Closer To Helping Hearing-Impaired Using Stem Cells 2NYU, Rockefeller researchers find complexity of regulation by microRNA genes 2Newer imaging techniques may lead to over-treatment 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Request Info...
... 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... to 1 mg/ml,(0.26 M to 2.6 mM) Sensitivity: around 0.2 ug/ml ...
See product name for description....
Biology Products: